Full Press Release Details
Cadrenal Therapeutics Provides Fourth Quarter
2023 Corporate Update
PONTE VEDRA, Fla., March
11, 2024 - Cadrenal Therapeutics, Inc.,
(Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner)
designed to prevent heart attacks, strokes and deaths due to blood clots in patients with rare cardiovascular conditions, today provided
a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023.
Founder, Chairman and Chief Executive Officer of Cadrenal Therapeutics, commented, "We believe there is a significant unmet need
and market opportunity for tecarfarin in patients with rare cardiovascular conditions requiring chronic anticoagulation. Specifically,
there is a lack of approved anticoagulation therapies for patients with left ventricular assist devices (LVADs), patients with end-stage
kidney disease (ESKD) and atrial fibrillation (AFib), and patients with thrombotic anti-phospholipid syndrome (APS)."
the past year, an increasing number of industry articles and presentations have concurred with our positioning, which we believe enhances
our opportunity from both a regulatory and commercial perspective. We have enhanced our intellectual property protection through the application
and receipt of orphan drug designations, which provides for 7 years of market exclusivity, engaged industry leaders to explore strategic
partnerships, co-development and licensing agreements for tecarfarin, and have expanded our manufacturing and supply chain capabilities
in preparation of an expected pivotal trial. These activities pave the way for what we believe will be an exciting year for Cadrenal."
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is developing tecarfarin for unmet needs in anticoagulation
therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths
due to blood clots in patients with rare cardiovascular conditions. Tecarfarin has orphan drug and fast track designations from the FDA
for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial
fibrillation (AFib). Cadrenal is also pursuing additional regulatory strategies for unmet needs in anticoagulation therapy for patients
with left ventricular assist devices (LVADs) and those with thrombotic antiphospholipid syndrome (APS). Tecarfarin is specifically designed
to leverage a different metabolism pathway than the oldest and most commonly prescribed Vitamin K Antagonist (warfarin). Tecarfarin has
been evaluated in eleven (11) human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials,
tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information,
please visit: www.cadrenal.com.
Safe Harbor Statement
Any statements contained in this press release about future expectations,
plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking
statements." These statements include statements regarding the two new potential rare medical
conditions increasing the total addressable market for tecarfarin to in excess of $2 billion in the U.S. annually, exploring strategic
partnerships, co-development, and licensing agreements for tecarfarin, there being a significant
unmet need and market opportunity for tecarfarin in patients with rare cardiovascular conditions requiring chronic anticoagulation, the
increasing number of industry articles and presentations having concurred with the Company's positioning, enhancing the Company's
opportunity from both a regulatory and commercial perspective, engaging industry leaders to explore strategic partnerships, co-development
and licensing agreements for tecarfarin, 2024 being an exciting year . The words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "will,"
"would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements
contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result
of various important factors, the ability to enter into strategic partnerships, the ability to treat
patients with rare cardiovascular conditions requiring chronic anticoagulation with tecarfarin,
the ability to enhance the Company's opportunity from both a regulatory and commercial perspective and the other risk factors
described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and the Company's subsequent
filings with the SEC, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking
statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company
specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events,
For more information, please contact:
Cadrenal Therapeutics:
Lytham Partners, LLC
Robert Blum, Managing Partner